|
ADHD, Big Pharma, and The Non-Science of Denial
2011-11-27 18:01:00 For ADHD Medications: Big Pharma Takes a Bum Wrap - In this Thanksgiving dialogue with Madelyn Griffith-Haynie, MCC, SCAC author of the blog ADD And So Much More I hit some of the high spots regarding my take on why Big Pharma has taken so much heat in ADHD land.
By: CorePsychBlog
Big Pharma's Top Ten Legal Drugs Linked to Violent Behavior
2011-02-11 18:54:00 Some medications have been linked to an increased risk for violent, even homicidal behavior. A recent study identified 31 drugs that are disproportionately linked with violent behavior. Time Magazine lists the top ten offenders: Varenicline (Chantix): The number one violence-inducing drug on the list, this anti-smoking medication is 18 times more likely to be linked with violence when compared to other drugs Fluoxetine (Prozac): This drug was the first well-known SSRI antidepressant Paroxetine (Paxil): Another SSRI antidepressant, Paxil is also linked with severe withdrawal symptoms and a risk of birth defects Amphetamines: (Various): Used to treat ADHD Mefoquine (Lariam): A treatment for malaria which is often linked with reports of strange behavior Atomoxetine (Strattera): An ADHD drug...
On the Subject of Direct-to-Consumer Marketing by Big Pharma
2010-10-26 17:22:00 "Say!� That KNEE REPLACEMENT PROSTHESIS I saw on TV last night looks SHARP!� Oughta GIT me one a those!" Saw a commercial last night that nearly floored me.� I have long wondered why Big Pharma feels it's necessary to advertise their prescription drugs -- the stuff YOU can't just walk into a drug store and ...
Video Essay: Digital Pharma East 2010
2010-10-22 13:21:00 I took a lot of video while at the Digital Pharma East 2010 conference this week in Philadelphia. I put this video wrap-up video really fast so that I could share this with all of you. (Apologize for all the non-ideal lighting. Hey, I'm not a videographer lol) The music is "Goodbye Philadelphia" by Peter Cincotti. I also invite you to read Post #1 and Post #2 from the meeting along with Doctor Anonymous Show 190. Thanks for a great meeting!
By: Doctor Anonymous
Panel: Digital Pharma East 2010
2010-10-20 20:09:00 I'm going to be leaving Philadelphia later today completing my time at Digital Pharma East 2010. I'd like to thank the organizers for asking me to be on a panel talking about the interface of pharma with physicians. The topic of this panel was similar to the discussion at Digital Pharma West this past summer. It was a very good discussion with interaction from the audience. The bottom line is - as of right now - even though docs are using mobile and smartphones a lot, physicians are not on social media. The question kept keeping up as far as, "How can docs access pharma in the internet space?" The answer is that you just can't, because docs are not on social. One point that was brought up was putting technology into the physician workflow. For example, putting things like pharma links into something like the EMR. In addition, wouldn't it be nice for me to see in the side bar whether the med I'm considering is on formulary or not on formulary. How about putting a link in my EM...
By: Doctor Anonymous
Update: Digital Pharma East 2010
2010-10-20 17:24:00 I'm having a great time here in Philadelphia at Digital Pharma East 2010. I'd like to thank the conference organizers for asking me to take part in the conference. I'll talk about the panel that I was on during a separate post. Usually during a meeting like this, I get to meet a lot of great people. And, I know that I'm going to probably offend someone if I don't mention everyone in this post. For that, I apologize. However, for me, the highlight during the conference was meeting Berci Mesko, MD who is the founder of Webicina and ScienceRoll.com. He spent 24 hours traveling from Hungary to take part in the conference. I remember interviewing Berci in the early days of The Doctor Anonymous Show. And, he woke up at about 2 or 3am to talk to me live from Hungary. We had a great conversation about social media. He told me that my blog and my internet radio show is a part of the curriculum for his Internet In Medicine University Course. We discussed me recording a video for his st...
By: Doctor Anonymous
Digital Pharma East 2010
2010-10-19 03:38:00 I'm going to Philadelphia for two days this week to be a part of what is called "The Most Innovative Event In Pharma History." It is called Digital Pharma East put on by Exl Pharma. Back at the end on June, I was asked to attend DigPharm West in San Francisco. I definitely learned a lot by going to that meeting. I encourage you to check out my blog post of when I was there. I'm going to be part of two panel discussions during this conference. The first one will be on Tuesday at 2:15pm. The title in the program is "Mobile Messaging To Health Care Providers." In this panel, will discuss "ways that mobile devices impact clinical workflow" and "how life sciences can use the mobile channels to provide value to the provider." The second session will be on Wednesday at 9:30am. The title is "The Changing Landscape Of Pharma/Physician Relationships." I'm on this panel with none other than @Doctor_V. If you would like to see the full schedule, check out the link here. One person I'm r...
By: Doctor Anonymous
Contract Pharma
2009-09-24 01:20:00 Devoted to pharmaceutical and biopharmaceutical contract services outsourcing, Contract Pharma is a must read for the pharmaceutical/biopharmaceutica-l industry professional.Request Free!
Codex Alimentarius ? Nahrungsmittel Diktatur f�r bessere Pharma-Ums�tze und
2009-09-10 19:22:00 Deine Gesundheit ist dank Elite & geldgierigen Lebensmittel- und Pharmaindustrie in Gefahr. Du glaubst es nicht? Die Ziele von Codex Alimentarius sind klar definiert: Aussagen �ber die heilende Wirkung von Vitaminen und anderen nat�rlichen Heilmitteln werden verboten und unter Strafe gestellt. In Zukunft wird nicht mehr von den Regierungen, sondern von der Pharma-Industrie bestimmt, was ...
Obama Pharma Deal - A Surprising Political Alliance
2009-08-11 23:35:00 A promise by the pharmaceutical industry to save the nation $80 billion over a decade in exchange for protection from further givebacks under health care reform pending in Congress was confirmed recently by the White House. Apparently, the pharmaceutical companies got spooked by action in the House that would give the feds negotiating authority for drug prices and bigger rebates from the industry. So the industry got an explicit affirmation of protection from deeper cuts. The trade group PhRMA explained the quid pro quo -- drugmakers stepped up first with a cost-saving pledge, and, in return, got "a rock-solid deal" not to make further cuts in prescription drug prices beyond the $80 billion. The White House confirmed the deal. Neither party mentioned what is apparently a side deal - drug companies will bankroll a TV ad campaign in support of health care reform. The ads would bolster the administration's plans to remake health care and expand insurance coverage to nearly 50 milli...
Update : Pharma Industry as per the latest Economical survey
2009-07-04 17:10:00 The pharma industry in the country has grown from mere Rs 1500 crore turnover in 1980 to over Rs 78,000 crore in 2008, with about 10 per cent share in the volume of global production, according to... [[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Update : Pharma Industry as per the latest Economical survey
2009-07-04 17:10:00 The pharma industry in the country has grown from mere Rs 1500 crore turnover in 1980 to over Rs 78,000 crore in 2008, with about 10 per cent share in the volume of global production, according to... [[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Jazz Pharma, Maguire Properties Soar, Hartford Plummet
2009-06-15 23:21:00 Jazz Pharmaceuticals Inc.'s ($4.23, +$1.59, +60.23%) sodium oxybate showed meaningful improvement in treating the pain and the main symptoms associated with fibromyalgia in Phase III studies. The company had already announced positive results from the trials late last year, saying preliminary results achieved their endpoints. Maguire Properties Inc. ($1.57, +$0.50, +46.73%), a struggling Los Angeles real-estate investment trust, sold a newly developed office building in Irvine, Calif., for about $160 million, a price representing an estimated 40% discount to its construction cost. Six Flags Inc. (SIXF, $0.15, -$0.11, -42.05%), one of the world's largest amusement-park chains, will be mostly owned by its lenders if a bankruptcy judge approves a deal negotiated between the company and its debt holders. The theme-park company filed for Chapter 11 bankruptcy protection early Saturday amid a mountain of debt topping $2 billion and a looming $300 million payment due to preferred sto...
By: Rant About It
Global pharma favorites
2009-05-06 15:00:00 In a review of the pharmaceutical sector, Chuck Carlson selects his favorite International stocks which also offer direct-purchase plans for U.S. investors.Here's a look at two of these stocks -- United Kingdom-based AstraZeneca (NYSE: AZN) and Denmark-based Novo Nordisk (NYSE: NVO) -- from his The DRIP Investor, a newsletter focused on long-term, high quality investments."AstraZeneca is a leading pharmaceutical firm. The company boasts a portfolio that includes 11 products that generate more than $1 billion each in annual sales. "Top drugs include Crestor (cholesterol) and Symbicort (asthma). Another important drug, the antipsychotic Seroquel, generated more than $4 billion in revenue last year. "However, the drug is at the center of more than 9,000 lawsuits from former Seroquel patients claiming the drug caused weight gain, high blood sugar levels, and even diabetes. "The U.S. government is also investigating the drug’s mark...
another wave of M & A in Pharma
2009-03-22 12:26:00 So far three deals that topping $150 billion in value have been announced in the global pharma industry this year. Merck & Co. acquired Schering Plough for $41 billion and Roche announced $47... [[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Possible Cure for Diabetes Found, Ignored by Big Pharma
2009-01-27 09:49:00 Irving Weissman discovered a treatment 12 years ago that might have saved the lives of thousands of women with advanced breast cancer, but pharmaceutical companies weren’t interested in developing the therapy. Though that interest is finally being reignited, Weissman doesn’t pull any punches. “I hate to say I told you so,” he said.Weissman is a professor of pathology & developmental biology at Stanford University, spoke Wednesday & Thursday as part of the Columbia University Department of Religion’s Bampton Lecture series. The lecture series is modeled after a centuries-old Oxford series of the same name, & invites famous authorities in their respective fields to give talks on various issues of interest to the religious community.In Wednesday’s lecture, Weissman laid out the conceptual foundation of his work—that stem cells are rare, self-renewing, & can regenerate body tissues. Weissman repeatedly expressed frustration that while plenty of of his discoveries seemed to...
Bristol-Myers (BMY): Favored pharma
2008-12-19 06:00:00 "Bristol-Myers Squibb (http://www.thestockadvisors.co-m/quote.htm?sym=bmy) (NYSE: BMY (http://www.thestockadvisors.co-m/quote.htm?sym=bmy)) comes in as the top performer on our 'Focus List'," says Alex Kolb (http://www.thestockadvisors.co-m/ccount/click.php?id=2666) in the top-notch advisory, Zacks Elite Stocks (http://www.thestockadvisors.co-m/ccount/click.php?id=2666). Here's his look at the pharmaceutical firm."Bristol-Myers Squibb is a major producer and distributor of pharmaceuticals and other healthcare related products. "The Pharmaceutical segment manufactures and sells branded pharmaceutical drugs such as Pravachol for cholesterol reduction, Plavix for hypertension and Erbitux for cancer."The Nutritional segment, through its subsidiary Mead Johnson, develops infant formulas like Enfamil, as well as other nutritional products. "Bristol Myers generates more than 55% of its revenue from the domestic market, and the balance from the international market primarily Europe,...
Hovione buys Pfizer's Pharma site
2008-12-17 17:31:00 Portuguese contract manufacturer Hovione has emerged as the buyer for Pfizer?s production plant in Cork, Ireland, which was put on the block last year. The site manufactures intermediates for... [[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Emami buys out Vaidyas in Zandu Pharma
2008-06-02 08:16:00 Emami Ltd on Friday bought out the entire stake of the Vaidya family, one of the two promoter groups, in Zandu Pharmaceutical Works Ltd. ... Click on Headline to read full Article..
Emami buys out Vaidyas in Zandu Pharma
2008-06-02 08:16:00 Emami Ltd on Friday bought out the entire stake of the Vaidya family, one of the two promoter groups, in Zandu Pharmaceutical Works Ltd. ... Click on Headline to read full Article..
Bafna Pharma IPO Allotment status and Allocation
2008-06-01 09:07:00 Bafna Pharma IPO Allotment status and allocation details will be updated here. Click here to see the allotment details of bafna pharma IPO
Some BIG PHARMA Facts. . .
2008-05-29 18:09:00 With dems (notably Obama) constantly declaring war on every major business that make our lives better I think it's appropriate to debunk some of dems attacks on our pharmaceutical industry: Time to develop and market a new drug: 10-15 years Average Cost to develop a new drug (2006): $1.318 billion Total R&D spending on drugs in 2007: $58.8 billion Generic share of market in 2007:... Click the Headline Link to Visit Copious Dissent and Read the Full Story.
Bafna Pharma IPO opens for subscription
2008-05-29 03:15:00 Bafna Pharmaceuticals will open for subscription today with its public issue of 64,00,000 equity shares of Rs 10 each at a price of Rs 40 per ... Click on Headline to read full Article..
Sun Pharma?s $454-Million Deal With Israel?s Taro Called Off
2008-05-28 18:03:00 It's not a done deal for Sun Pharmaceuticals. The Mumbai based pharma company's last year's $454 million deal to acquire Israel's Taro Pharmaceut10 Vote(s)
By: Market Buzz
Plethico Pharma Stock Split
2008-05-28 06:44:00 Plethico Pharmaceuticals Stock Split has been announced by the company. In an annoucment made the company has informed the BSE that the board at its meeting held on May 27 has recommended dividend...[[ This is a content summary only. Vi3 Vote(s)
By: Market Buzz
Pharma stocks regain investors' interest
2008-05-27 16:04:00 'Plenty of growth opportunities for generic cos' Mumbai, May 26 The market might be in a very volatile phase but the pharma stocks seem to be quite fortified from the market volati6 Vote(s)
By: Market Buzz
Tonira Pharma
2008-05-23 11:15:00 Tonira Pharma has got US FDA approval for its manufacturing facility located in vadodara. Company can now concentrate on Export Market now. Anyone... Click on Headline to read full Article..
Bafna Pharma IPO
2008-05-20 13:16:00 Bafna Pharma IPO opens on May 27 Price per share 40.Rs addthis_url = 'http%3A%2F%2Fbirlaa.com%2F2008-%2F05%2F20%2Fbafna-pharma-ipo-2-%2F'; ... Click on Headline to read full Article..
Sun Pharma Advanced Research Company
2008-05-20 08:02:00 Buy Sun Pharma Advanced Research Company Stop loss of Rs 88 Target of Rs 1232 Vote(s)
By: Market Buzz
BAFNA Pharma IPO Subscription Date
2008-05-18 21:16:00 Bafna Pharmaceuticals IPO is scheduled to open for subscription on May 27, 2008. It is a fixed price IPO. IPO price has been fixed at Rs. 40 per share of face value Rs. 10 each. The public issue opens for subscription on Tuesday, May 27, 2008 and will close for subscription on May 30, 2008. ...
PHARMA GAINS FROM DIABETES
2008-05-15 12:11:00 Source: Times of India 6th May?08, (Tuesday)Mumbai: Diabetes, Cardiac and gastrointestinal hold sway in India, where chronic therapies comprise more than 40% of the entire market. Like developed markets, India is gradually shifting to lifestyle disorders. And drug companies are profiting form diabetes and cardiovascular cases.The over searching trend of lifestyle diseases is dictating the fortunes of various therapeutic categories. Prescriptions for diabetes have grown over 15% compounded since 2000 in urban India. With India poised to have the largest number diabetics in future, the antidiabetic therapeutic area has had the highest growth rate of 26.1%, followed by cardiology at 21.3% and gynaecology at 18.3%, according to ORG-IMS data. The antidiabetic segment has grown from 19.5 %( MAT December 2006) to 26.1%(MAT December 2007). The gynaecology segment too recorded growth from 15.9% to 18.3% m during the same period.Not only are drug majors benefiting from the growing cases of di...
PHARMA GAINS FROM DIABETES
2008-05-15 12:10:00 Source: Times of India 6th May?08, (Tuesday)Mumbai: Diabetes, Cardiac and gastrointestinal hold sway in India, where chronic therapies comprise more than 40% of the entire market. Like developed markets, India is gradually shifting to lifestyle disorders. And drug companies are profiting form diabetes and cardiovascular cases.The over searching trend of lifestyle diseases is dictating the fortunes of various therapeutic categories. Prescriptions for diabetes have grown over 15% compounded since 2000 in urban India. With India poised to have the largest number diabetics in future, the antidiabetic therapeutic area has had the highest growth rate of 26.1%, followed by cardiology at 21.3% and gynaecology at 18.3%, according to ORG-IMS data. The antidiabetic segment has grown from 19.5 %( MAT December 2006) to 26.1%(MAT December 2007). The gynaecology segment too recorded growth from 15.9% to 18.3% m during the same period.Not only are drug majors benefiting from the growing cases of di...
Aventis Pharma launches SoloStar in India
2008-05-14 05:25:00 Aventis Pharma Limited, a Sanofi-Aventis group company, has launched a new prefilled disposable insulin pen SoloStar for use with the 24-hour insulin Lantus."The insulin market in India is about Rs 410 crore and we have captured a market of about 7% with Lantus. The launch of SoloStar will boost our market share by another 1-2%," said Susheel Umesh, senior director, Cardio-Metabolism Business Unit who was in Ahmedabad for the launch. The Chicago Athenaeum Museum of Architecture and Design awarded the 2007 Good Design award to SoloStar.Lantus has a global market of 2 billion Euros. SoloStar reduces the injection force by 30% or more in comparison to other leading disposable pens, he added.According to diabetologist Sanjeev Phatak after Tamil Nadu, Gujarat has highest prevalence of diabetes. "There would be 30-40 lakh diabetes patients in Gujarat of which about 4-5 lakh would be in Ahmedabad," Phatak said.Source: business-standard.com
Researchreports) Urgent Requierd Report on SMS Pharma
2008-05-09 16:45:00 Dear All Plz frwd any broking house report on SMS Pharma ITS URGENT
surya pharma
2008-05-04 06:42:00 invest here and now. worst is over for surya pharma Home About Us BSEAnnouncements Indices Public I-ssues Reverse Bookbuilding& Buyback Listing CorporateFilings BSE TrainingInstitute My BSE Top Gainers ...
Various non academic jobs at GNDU Amritsar
2008-04-27 15:02:00 Name and Address of Company: GURU NANAK DEV UNIVERSITY (GNDU), AMRITSAR (Established by the State Legislature Act No.21 of 1969) GT Road, Amritsar, Punjab India Advertisement No. 3/2008 Applications are invited for the following posts on the prescribed application form so as to reach this office latest by 21.05.2008. 1. Divisional Accountant : 01 post (on contractual basis initially for ...
Jobs at UPSC Advt. No. 08/2008
2008-04-26 13:12:00 Name and Address of Company: Union Public Service Commission (UPSC) UPSC invites application on prescribed forms by 15th May 2008 (22nd May 2008 for the candidates from far flung areas) for various posts in various Government of India Ministries and Departments in the prescribed format. The post are : 1. One Professor (English) in National Defence Academy, Khadakwasla, ...
Troikaa Pharma plans EoU in A`bad
2008-04-25 05:09:00 Setting its sights on becoming a Rs 500-crore turnover company by 2012, Ahmedabad-based Troikaa Pharma is set to strengthen its focus on export markets.The company is planning to set up an export-oriented unit (EoU) at Sanand near Ahmedabad to manufacture critical care injectables, tablets and topical preparations. Its current facility in Dehra Dun will also see expansion this year.The new unit at Sanand will come up over an area of 75 acres for which land has already been acquired. The plant would being operations from from February 2009. Close to Rs 120 crore will be invested in the new unit, which will funded through internal accruals.?Exports form nearly 60 percent of our revenues. We are looking at newer export markets like Brazil, Mexico, South Africa, Columbia, Thailand and Phillipines,? said Ketan Patel, MD of Troikaa Pharma.The company is expecting a 40 per cent push to its topline and bottomline in the coming years on account of exports. The turnover for the year 2007-2008...
Big Pharma Uses Direct Tactics to Beat Parallel Traders
2008-04-22 17:19:00 Parallel traders are the thorn in the side for pharmaceutical companies operating in Europe. Local sales mangers see their bottom line eroded as independent exporters undercut them with their own product! The considerable efforts that pharma companies have gone to prevent this grey trade have largely failed. The majority of legal actions against traders ...
Dabur Pharma: Is it undervalued?
2008-04-22 00:02:00 By Priya Nigam?Consolidation? has been the name of the game across the world this year. The news so far in 2008 has been dotted by mergers and acquisitions. Despite the US credit crisis and the tight global financial situation, the value of M&A deals this year has surged passed the $1 trillion mark. Closer to home, however, the story has been different. In India, the value of M&A deals has plummeted almost 72% year-on-year. This is notwithstanding Tata Motors Ltd?s offer to take over Jaguar and Land Rover from Ford Motor Co.Another interesting deal in the Indian market involves the offer to buy a 73.3% control of oncology major Dabur Pharma. The company has announced that its promoters (the Burman family) and certain other stockholders have agreed to sell their shares to Singapore-based Fresenius Kabi Pte Ltd for Rs76.50 per share. Fresenius Kabi is a 100% subsidiary of the $12 billion German healthcare group Fresenius SE. The deal, which costs the global giant Rs878.2 crore...
By: The India Street
Pharma Vacancies
2008-04-21 13:45:00 Kami mengundang kandidat fresh graduate ataupun berpengalaman untuk beberapaposisi di perusahaan kami:1. Pharmacist- Untuk ditempatkan di bagian produksi atau di packaging- Telah mengikuti program profesi apoteker2. Engineering Staff- minimal D3 Teknik Mesin atau Elektro3. Asisten Apoteker- lulus dari Sekolah Menengah Farmasi (SMF) atau D3 FarmasiKirimkan CV Anda keAndreas.purnawan@darya-varia.-com
By: lowongan kerja
Ankur Drugs And Pharma Limited
2008-04-14 09:52:00 Free Intraday Tips for 15th April 08SASKEN ( Sasken Communication Technologies Ltd) ActionTrigger Price Stop LossTarget 1 Target 2BUY ABOVE138135144153S.SELL BELOW132136127118Click here for more recommendations of stocks below Rs.150 ANKURDRUGS ( Ankur Drugs And Pharma Limited) ActionTrigger Price Stop LossTarget 1 Target 2BUY ABOVE210204219229S.SELL BELOW201206195178SELAN ( Selan Exploration Technology Ltd) ActionTrigger Price Stop LossTarget 1Target 2BUY ABOVE188182198210S.SELL BELOW179183171153Read more... Did You Enjoy this Post?Subscribe Today. Click here for more recommendations of stocks below Rs.150 Click here to Get Tips for your own Stocks
Code of Conduct for pharma industry bars ‘exotic’ offers for doctors
2008-04-12 19:04:00 By Bandula SirimannaThe newly amended Code of Marketing Pharmaceutical Practices has laid down strict guidelines preventing the offering or providing of any favours including foreign trips for medical practitioners in return for prescribing drugs.The pharmaceutical industry which had come under some criticism in the recent past for alleged unethical marketing practices has laid down in its Code with some strong restrictions for its members which include linking sponsorships to International /Local medical Congresses, to any obligation to prescribe, recommend or promote any pharmaceutical product.The Sri Lanka Chamber for Pharmaceutical Industry (SLCPI) Code also specifically prohibits members from organising any social events for doctors and clearly states that any sponsorship which involves symposiums or professional meetings should be purely to inform about healthcare products or provide scientific or educational information that would benefit the healthcare professionals and the ...
EXCISE ON PHARMA; LOAD ON CONSUMER
2008-03-22 08:02:00 In a first-of-its-kind move, the drug price regulator asked pharmaceutical companies to pass on the benefit of the recent excise duty cut to consumers even on medicines that are outside government’s price control. This will reduce prices by 4.58% on brands that account for three fourth of the Rs 33,000-crore domestic pharmaceutical market. While intervening in the control-free segment of the market for the first time to emphasise that excise cut benefit should be passed on to consumers, the price regulator said emphatically that companies “must” reduce prices. The regulator also said it will use a public interest clause in the drug pricing law to enforce Monday’s order. Finance minister P Chidambaram had halved the excise duty on all medicines from 16 % to 8 % in this year’s budget. Excise duty will now be levied on 64.5% of the MRP instead of 57.5% earlier. This works out to a 4.58% cut in the MRP on all medicines. Drug makers have to s...
By: India Blog
DHG Pharma to buy back stock
2008-03-20 05:20:00 DHG Pharmaceutical Joint ? Stock Company (DHG Pharma) will repurchase its shares as follows: Stock symbol: DHG Number of treasury shares before trading: 2,280 shares Number of shares registered to buy back: 490 shares Number of treasury shares after trading: 2,770 shares Purpose: to buy back the preferred shares... [[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Despite Challenges- Big Pharma Companies Turn Attention to Emerging Markets
2008-03-19 16:41:00 Faced with dwindling growth rates in the US and Europe, pharmaceutical companies are turning their attention towards emerging pharmaceutical markets whose double-digit growth is fuelled by their recent economic booms. However, although the patient potential of the emerging market countries is enormous, foreign pharma companies are currently tapping into only a fraction of the consumers, ...
Teva to expand pharma plant - Prague Post
2008-03-13 19:36:00 Teva to expand pharma plantPrague Post, Czech Republic - 5 hours ...
By: Israel-Times.com
Reliance plans pharma unit in Jamnagar
2008-03-07 01:21:00 While company executives refused to divulge further details, industry sources said that Reliance has earmarked a huge area in the SEZ for the project.9 Vote(s)
By: Market Buzz
Sciele Pharma And Plethora Solutions Holdings PLC Announce Initiation Of Pi
2008-03-07 01:02:00 The service of PSD502 in the service of the treatment of untimely ejaculation.May 2007, Sciele signed an licensing concord in the service of PSD502 with Plethora Solutions.PSD502 is a proprietary formulation of two marketed drugs - lidocaine and prilocaine - dispensed by a metered administer aerosol and developed in the service of the treatment of untimely ejaculation, a disorder affecting up to 30% of men in Europe and the U.And in the service of which there currently is no FDA-approved medication treatment.Offering is applied locally when needed ( continually referred to as "on demand" therapy) and is serviceable within five minutes.Offering has been shown to dilate ejaculation latency duration whenpared with placebo in a multi-center wind up II investigation This figures was published recently in BJU universal _(Dinsmore W et al 2007, BJU Int 99: 369-35)_.Patrick Fourteau, President and Chief director copper of Sciele Pharma, said, "We are tickled pink with the capital at work Pl...
By: medicine news
Quotes from Bio-Pharma Development Summit
2008-02-27 10:28:00 ?Today, companies have to realise that it?s not only about competing, but also about co-operating.? ? Malvinder Singh, MD & CEO, Ranbaxy Laboratories?The challenge in R&D is to keep people going on a project for 10 years and deciding if bonus is to be paid if it fails.? ? Shiv Raman Dugal, Chairman, ICRI?India?s current challenge in healthcare and research and development will be its future strength? ? Ted Bianco, Director, Wellcome Trust?We came to India looking for cheap hands, but after three years, we realise that we are staying here for the brains.? ? Dr. Naveen Rao, Managing Director, Merck & Co, India?Incremental research, reverse pharmacology and research in herbal products offer attractive opportunities? ? Pratibha Pilgaonkar, CEO, Rubicon Research?We have a drug offering a real possibility of eradicating Kala Azar, through public-private partnership? ? Kavita Khanna, President, Bharat Serums & Vaccines?India offers a fast track alternative to clinical R&... |
|
 |
|
 |
